Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia.

@article{Kim2010ImpactOA,
  title={Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia.},
  author={Theo Daniel Kim and Seval Tuerkmen and Michaela Schwarz and G{\"o}kben Koca and Hendrik Nogai and Christiane Bommer and Bernd Doerken and Peter Daniel and Philipp le Coutre},
  journal={Haematologica},
  year={2010},
  volume={95 4},
  pages={
          582-8
        }
}
BACKGROUND Additional chromosomal aberrations in Philadelphia chromosome-positive chronic myeloid leukemia are non-random and strongly associated with disease progression, but their prognostic impact and effect on treatment response is not clear. Point mutations in the BCR-ABL kinase domain are probably the most common mechanisms of imatinib resistance. DESIGN AND METHODS We assessed the influence of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to the… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 20 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 45 REFERENCES

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.

  • The New England journal of medicine
  • 2006
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL